SUPPLEMENTAL DIGITAL CONTENT 3

SUPPLEMENTAL TABLE 2. Most prevalent treatment-emergent NNRTI and N(t)RTI RAMs (in 2 or more patients with available resistance data in either treatment group) at the time of week 48 analysis

	RPV 25 mg QD N = 686	EFV 600 mg QD N = 682
VF_{res}, n (%)	72 (10)	39 (6)
Rebounders	29 (4)	20 (3)
Never suppressed	43 (6)	19 (3)
VF_{res} with resistance data at time of failure	N = 62	N = 28
VF_{res} with no treatment-emergent NNRTI and/or IAS-USA N(t)RTI RAM[13]	18/62 (29)	12/28 (43)
VF_{res} with any treatment-emergent NNRTI RAM, n (%)	39/62 (63)	15/28 (54)
VF_{res} with any treatment-emergent IAS-USA N(t)RTI RAM,[13] n (%)	42/62 (68)	9/28 (32)
VF_{res} with any treatment-emergent NNRTI and/or IAS-USA N(t)RTI RAM,[13] n (%)	44/62 (71)	16/28 (57)
VF_{res} with any treatment-emergent NNRTI and IAS-USA N(t)RTI RAM,[13] n (%)	37/62 (60)	8/28 (29)
NNRTI RAM incidence in patients who failed with NNRTI mutations, n (%)	N' = 39	N' = 15
E138K	28/39 (72)	0
K103N	0	11/15 (73)
K101E	8/39 (21)	1/15 (7)
H221Y	6/39 (15)	0
V90I	5/39 (13)	0
Y181C	5/39 (13)	0
V189I	5/39 (13)	0
V106M	0	3/15 (20)
L100I	2/39 (5)	1/15 (7)
V179I	2/39 (5)	0
E138Q	2/39 (5)	0

F227C	2/39 (5)	0
Y188C	0	2/15 (13)
IAS-USA N(t)RTI RAM incidence in patients who failed with N(t)RTI mutations, n (%)	N' = 42	N' =9
M184I	29/42 (69)	2/9 (22)
M184V	14/42 (33)	6/9 (67)
K219E	3/42 (7)	0
K65R*	3/42 (7)	2/9 (22)
Y115F	2/42 (5)	0
K65N	2/42 (5)	0
A62V	2/42 (5)	0

*Only observed with subtype C virus; RPV, rilpivirine; EFV, efavirenz; QD, once daily; VF_{res}=virologic failure using the resistance analysis defined as any patient in the intent-to-treat population experiencing treatment failure regardless of time of failure, treatment status or reason for discontinuation providing the following criteria were met: never achieved 2 consecutive viral load values <50 copies per milliliter and had an increase in viral load ≥0.5 $\log_{10}$ copies per milliliter above the nadir (never suppressed) or first achieved 2 consecutive viral load values <50 copies per milliliter followed by 2 consecutive (or single, when last available) viral load values ≥50 copies per milliliter (rebounder); NNRTI=non-nucleoside reverse transcriptase inhibitor; RAM=resistance-associated mutation; IAS-USA=International AIDS Society-USA; N(t)RTI=nucleoside/nucleotide reverse transcriptase inhibitor. N=number of patients in each treatment group; N' or N'', number of evaluable patients in each treatment group; n=number of observations.